StreetInsider.com News Articles

Form 8-K INTERPACE BIOSCIENCES, For: May 12

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495198.html

Form 8-K INTERPACE BIOSCIENCES, For: May 12

Thu, 14 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260514/26495198.html

Interpace Biosciences (IDXG) Reports Q1 EPS of $0.03

Tue, 12 May 2026 17:55:51 -0400

Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.03. Revenue for the quarter came in at $9.03 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

Form 10-Q INTERPACE BIOSCIENCES, For: Mar 31

Tue, 12 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260512/26478591.html

Form 10-Q INTERPACE BIOSCIENCES, For: Mar 31

Tue, 12 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260512/26478591.html

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Tue, 12 May 2026 16:06:00 -0400

Q1 Revenue of $9.0 million
Q1 Income from Continuing Operations of $0.8 million
Q1 Thyroid volume year-over-year increase of 10%
Q1 Thyroid revenue year-over-year increase of 12%

PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.

Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations, and produced Adjusted EBITDA of $1.6 million, or 17% of revenue.

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Tue, 12 May 2026 16:06:00 -0400

Q1 Revenue of $9.0 million
Q1 Income from Continuing Operations of $0.8 million
Q1 Thyroid volume year-over-year increase of 10%
Q1 Thyroid revenue year-over-year increase of 12%

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Tue, 12 May 2026 16:06:00 -0400

Q1 Revenue of $9.0 million
Q1 Income from Continuing Operations of $0.8 million
Q1 Thyroid volume year-over-year increase of 10%
Q1 Thyroid revenue year-over-year increase of 12%

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results

Tue, 12 May 2026 16:06:00 -0400

Q1 Revenue of $9.0 million
Q1 Income from Continuing Operations of $0.8 million
Q1 Thyroid volume year-over-year increase of 10%
Q1 Thyroid revenue year-over-year increase of 12%

Form 10-K/A INTERPACE BIOSCIENCES, For: Dec 31

Thu, 30 Apr 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260430/26408963.html

Form 10-K/A INTERPACE BIOSCIENCES, For: Dec 31

Thu, 30 Apr 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260430/26408963.html

Form 8-K INTERPACE BIOSCIENCES, For: Mar 30

Wed, 01 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260401/26259397.html

Form 8-K INTERPACE BIOSCIENCES, For: Mar 30

Wed, 01 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260401/26259397.html

Interpace Biosciences (IDXG) Reports Q4 EPS of $0.82

Tue, 31 Mar 2026 06:18:41 -0400

Interpace Biosciences (OTC: IDXG) reported Q4 EPS of $0.82.Revenue for the quarter came in at $9.22 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.

Form 10-K INTERPACE BIOSCIENCES, For: Dec 31

Mon, 30 Mar 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260330/26241544.html

Form 10-K INTERPACE BIOSCIENCES, For: Dec 31

Mon, 30 Mar 2026 17:43:00 -0400

si-local-file:///var/storage/secattach/20260330/26241544.html

Form 4 INTERPACE BIOSCIENCES, For: Jan 20 Filed by: 1315 Capital II, L.P.

Tue, 17 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260217/26012450.html

Form 4 INTERPACE BIOSCIENCES, For: Jan 20 Filed by: 1315 Capital II, L.P.

Tue, 17 Feb 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260217/26012450.html

Form 4 INTERPACE BIOSCIENCES, For: Jan 20 Filed by: Ampersand 2018 Limited Partnership

Wed, 04 Feb 2026 18:46:00 -0400

si-local-file:///var/storage/secattach/20260204/25948610.html

Form 4 INTERPACE BIOSCIENCES, For: Jan 20 Filed by: Ampersand 2018 Limited Partnership

Wed, 04 Feb 2026 18:46:00 -0400

si-local-file:///var/storage/secattach/20260204/25948610.html

Form 8-K INTERPACE BIOSCIENCES, For: Jan 20

Tue, 20 Jan 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260120/25865820.html

Form 8-K INTERPACE BIOSCIENCES, For: Jan 20

Tue, 20 Jan 2026 09:06:00 -0400

si-local-file:///var/storage/secattach/20260120/25865820.html

Form 8-K INTERPACE BIOSCIENCES, For: Dec 03

Wed, 03 Dec 2025 16:05:00 -0400

si-local-file:///var/storage/secattach/20251203/25695409.html

Form 8-K INTERPACE BIOSCIENCES, For: Dec 03

Wed, 03 Dec 2025 16:05:00 -0400

si-local-file:///var/storage/secattach/20251203/25695409.html

Interpace Biosciences (IDXG) Reports Q3 EPS of $0.04

Thu, 13 Nov 2025 06:23:46 -0400

Interpace Biosciences (OTC: IDXG) reported Q3 EPS of $0.04. Revenue for the quarter came in at $8.76 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.